Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications

References

• Nicolaidis S. Environment and obesity. Metabolism. 2019;100:153942. doi:10.1016/j.metabol.2019.07.006
   Google Scholar
• Gregory JW. Prevention of obesity and metabolic syndrome in children. Front Endocrinol (Lausanne). 2019;10:669. doi:10.3389/fendo.2019.00669
   PubMedGoogle Scholar
• Hruby A, Manson JE, Qi L, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656–1662. doi:10.2105/AJPH.2016.303326
   PubMed Web of Science ®Google Scholar
• NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–1396. doi:10.1016/S0140-6736(16)30054-X
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–1932. doi:10.1016/j.jacc.2008.12.068
   PubMed Web of Science ®Google Scholar
• Koene RJ, Prizment AE, Blaes A, et al. Shared Risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. doi:10.1161/CIRCULATIONAHA.115.020406
   PubMed Web of Science ®Google Scholar
• Yu YH. Making sense of metabolic obesity and hedonic obesity. J Diabetes. 2017;9(7):656–666. doi:10.1111/1753-0407.12529
   PubMedGoogle Scholar
• Zhu Y, Zheng H, Zou Z, et al. Metabolic syndrome and related factors in Chinese children and adolescents: analysis from a Chinese national study. J Atheroscler Thromb. 2019. doi:10.5551/jat.50591
   Google Scholar
• Xu W, Zhang H, Paillard-Borg S, et al. Prevalence of overweight and obesity among Chinese Adults: role of adiposity indicators and age. Obes Facts. 2016;9(1):17–28. doi:10.1159/000443003
   PubMed Web of Science ®Google Scholar
• Lv X, Zhou W, Sun J, et al. Visceral adiposity is significantly associated with type 2 diabetes in middle-aged and elderly Chinese women: a cross-sectional study. J Diabetes. 2017;9(10):920–928. doi:10.1111/1753-0407.12499
   PubMedGoogle Scholar
• Thottam GE, Krasnokutsky S, Pillinger MH. Gout and metabolic syndrome: a tangled web. Curr Rheumatol Rep. 2017;19(10):60. doi:10.1007/s11926-017-0688-y
   PubMed Web of Science ®Google Scholar
• Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820. doi:10.1155/2015/762820
   PubMed Web of Science ®Google Scholar
• Qasim A, Turcotte M, de Souza RJ, et al. On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations. Obesity Rev. 2018;19(2):121–149. doi:10.1111/obr.v19.2
   PubMed Web of Science ®Google Scholar
• Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci (Lond). 2016;130(12):943–986.
   PubMed Web of Science ®Google Scholar
• Waalen J. The genetics of human obesity. Transl Res. 2014;164(4):293–301. doi:10.1016/j.trsl.2014.05.010
   PubMed Web of Science ®Google Scholar
• Choquet H, Meyre D. Molecular basis of obesity: current status and future prospects. Curr Genomics. 2011;12(3):154–168. doi:10.2174/138920211795677921
   PubMed Web of Science ®Google Scholar
• Yu Z, Han S, Cao X, et al. Genetic polymorphisms in adipokine genes and the risk of obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2012;20(2):396–406. doi:10.1038/oby.2011.148
   PubMed Web of Science ®Google Scholar
• Cecil JE, Palmer CN, Fischer B, et al. Variants of the peroxisome proliferator-activated receptor gamma- and beta-adrenergic receptor genes are associated with measures of compensatory eating behaviors in young children. Am J Clin Nutr. 2007;86(1):167–173. doi:10.1093/ajcn/86.1.167
   PubMedGoogle Scholar
• Ariza M, Garolera M, Jurado MA, et al. Dopamine genes (DRD2/ANKK1-TaqA1 and DRD4-7R) and executive function: their interaction with obesity. PLoS One. 2012;7(7):e41482. doi:10.1371/journal.pone.0041482
   PubMed Web of Science ®Google Scholar
• Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes. 2008;57(1):95–101. doi:10.2337/db07-0910
   PubMed Web of Science ®Google Scholar
• Qi Q, Chu AY, Kang JH, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med. 2012;367(15):1387–1396. doi:10.1056/NEJMoa1203039
   PubMed Web of Science ®Google Scholar
• Rohde K, Keller M, la Cour Poulsen L, et al. Genetics and epigenetics in obesity. Metabolism. 2019;92:37–50. doi:10.1016/j.metabol.2018.10.007
   PubMed Web of Science ®Google Scholar
• Landrier J-F, Derghal A, Mounien L. MicroRNAs in obesity and related metabolic disorders. Cells. 2019;8(8):859. doi:10.3390/cells8080859
   PubMed Web of Science ®Google Scholar
• Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206. doi:10.1038/nature14177
   PubMed Web of Science ®Google Scholar
• Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187–196. doi:10.1038/nature14132
   PubMed Web of Science ®Google Scholar
• Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. lancet Diabetes Endocrinol. 2018;6(3):223–236. doi:10.1016/S2213-8587(17)30200-0
   PubMed Web of Science ®Google Scholar
• Major TJ, Dalbeth N, Stahl EA, et al. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018;14(6):341–353. doi:10.1038/s41584-018-0004-x
   PubMed Web of Science ®Google Scholar
• Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 1964;36(4):561–570. doi:10.1016/0002-9343(64)90104-4
   PubMedGoogle Scholar
• Aune D, Norat T, Vatten LJ. Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies. Eur J Nutr. 2014;53(8):1591–1601. doi:10.1007/s00394-014-0766-0
   PubMed Web of Science ®Google Scholar
• Lyngdoh T, Vuistiner P, Marques-Vidal P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 2012;7(6):e39321. doi:10.1371/journal.pone.0039321
   PubMed Web of Science ®Google Scholar
• Larsson SC, Burgess S, Michaelsson K. Genetic association between adiposity and gout: a Mendelian randomization study. Rheumatology (Oxford). 2018;57(12):2145–2148. doi:10.1093/rheumatology/key229
   PubMed Web of Science ®Google Scholar
• Gali Ramamoorthy T, Begum G, Harno E, et al. Developmental programming of hypothalamic neuronal circuits: impact on energy balance control. Front Neurosci. 2015;9:126. doi:10.3389/fnins.2015.00126
   PubMed Web of Science ®Google Scholar
• Haggarty P. Genetic and metabolic determinants of human epigenetic variation. Curr Opin Clin Nutr Metab Care. 2015;18(4):334–338. doi:10.1097/MCO.0000000000000194
   PubMedGoogle Scholar
• Zhang Y, Ren J. Epigenetics and obesity cardiomyopathy: from pathophysiology to prevention and management. Pharmacol Ther. 2016;161:52–66. doi:10.1016/j.pharmthera.2016.03.005
   PubMed Web of Science ®Google Scholar
• Yara S, Lavoie JC, Levy E. Oxidative stress and DNA methylation regulation in the metabolic syndrome. Epigenomics. 2015;7(2):283–300. doi:10.2217/epi.14.84
   PubMed Web of Science ®Google Scholar
• Jiang X, Ye X, Guo W, et al. Inhibition of HDAC3 promotes ligand-independent PPARgamma activation by protein acetylation. J Mol Endocrinol. 2014;53(2):191–200. doi:10.1530/JME-14-0066
   PubMedGoogle Scholar
• Arner P, Kulyte A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11(5):276–288. doi:10.1038/nrendo.2015.25
   PubMed Web of Science ®Google Scholar
• Marques-Rocha JL, Samblas M, Milagro FI, et al. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 2015;29(9):3595–3611. doi:10.1096/fj.14-260323
   PubMed Web of Science ®Google Scholar
• Deiuliis JA. MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond). 2016;40(1):88–101. doi:10.1038/ijo.2015.170
   PubMed Web of Science ®Google Scholar
• Kulcheski FR, Christoff AP, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51. doi:10.1016/j.jbiotec.2016.09.011
   PubMed Web of Science ®Google Scholar
• Yerlikaya A, Dagel T, King C, et al. Dietary and commercialized fructose: sweet or sour? Int Urol Nephrol. 2017;49(9):1611–1620. doi:10.1007/s11255-017-1544-8
   PubMedGoogle Scholar
• Cleophas MC, Crişan TO, Lemmers H, et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann Rheum Dis. 2016;75(3):593–600. doi:10.1136/annrheumdis-2014-206258
   PubMed Web of Science ®Google Scholar
• Jin HM, Kim T-J, Choi J-H, et al. MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Res Ther. 2014;16(2):R88. doi:10.1186/ar4531
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Pool B, Shaw OM, et al. Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals. Ann Rheum Dis. 2015;74(4):786–790. doi:10.1136/annrheumdis-2014-205409
   PubMedGoogle Scholar
• Park HK, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism. 2015;64(1):24–34. doi:10.1016/j.metabol.2014.08.004
   PubMed Web of Science ®Google Scholar
• Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol. 2014;171(2):314–331. doi:10.1111/bph.12324
   PubMedGoogle Scholar
• Macneil DJ. The role of melanin-concentrating hormone and its receptors in energy homeostasis. Front Endocrinol (Lausanne). 2013;4:49. doi:10.3389/fendo.2013.00049
   PubMedGoogle Scholar
• Peterson SM, Pack TF, Wilkins AD, et al. Elucidation of G-protein and beta-arrestin functional selectivity at the dopamine D2 receptor. Proc Natl Acad Sci U S A. 2015;112(22):7097–7102. doi:10.1073/pnas.1502742112
   PubMedGoogle Scholar
• Heyman E, Gamelin F-X, Aucouturier J, et al. The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity. Obes Rev. 2012;13(12):1110–1124. doi:10.1111/obr.2012.13.issue-12
   PubMedGoogle Scholar
• Nathan PJ, Bullmore ET. From taste hedonics to motivational drive: central mu-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol. 2009;12(7):995–1008. doi:10.1017/S146114570900039X
   PubMed Web of Science ®Google Scholar
• Fang PH, Yu M, Ma Y-P, et al. Central nervous system regulation of food intake and energy expenditure: role of galanin-mediated feeding behavior. Neurosci Bull. 2011;27(6):407–412. doi:10.1007/s12264-011-1841-7
   PubMedGoogle Scholar
• Hayes DJ, Greenshaw AJ. 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev. 2011;35(6):1419–1449. doi:10.1016/j.neubiorev.2011.03.005
   PubMedGoogle Scholar
• Kovacs KJ. CRH: the link between hormonal-, metabolic- and behavioral responses to stress. J Chem Neuroanat. 2013;54:25–33. doi:10.1016/j.jchemneu.2013.05.003
   PubMedGoogle Scholar
• Sohn JW. Network of hypothalamic neurons that control appetite. BMB Rep. 2015;48(4):229–233. doi:10.5483/BMBRep.2015.48.4.272
   PubMed Web of Science ®Google Scholar
• Lin Y, Hall RA, Kuhar MJ. CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist. Neuropeptides. 2011;45(5):351–358. doi:10.1016/j.npep.2011.07.006
   PubMedGoogle Scholar
• Loh K, Herzog H, Shi YC. Regulation of energy homeostasis by the NPY system. Trends Endocrinol Metab. 2015;26(3):125–135. doi:10.1016/j.tem.2015.01.003
   PubMed Web of Science ®Google Scholar
• Adamska E, Ostrowska L, Górska M, et al. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Prz Gastroenterol. 2014;9(2):69–76. doi:10.5114/pg.2014.42498
   PubMedGoogle Scholar
• Simpson K, Parker J, Plumer J, Bloom S. CCK, PYY and PP: the control of energy balance. In: Handb Exp Pharmacol. Berlin, Heidelberg: Springer; 2012:209–230.
   Google Scholar
• Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav. 2010;100(5):511–518. doi:10.1016/j.physbeh.2010.03.001
   PubMedGoogle Scholar
• Begg DP, Woods SC. The central insulin system and energy balance. In: Handb Exp Pharmacol. Berlin, Heidelberg: Springer; 2012:111–129.
   Google Scholar
• Gahete MD, Rincón-Fernández D, Villa-Osaba A, et al. Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight. J Endocrinol. 2014;220(1):R1–R24. doi:10.1530/JOE-13-0391
   PubMedGoogle Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
   PubMed Web of Science ®Google Scholar
• Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6(5):398–405. doi:10.1016/j.cmet.2007.10.008
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G-J, Tomasi D, et al. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013;14(1):2–18. doi:10.1111/obr.2013.14.issue-1
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci. 2011;15(1):37–46. doi:10.1016/j.tics.2010.11.001
   PubMed Web of Science ®Google Scholar
• D’Addario C, Micioni Di Bonaventura MV, Pucci M, et al. Endocannabinoid signaling and food addiction. Neurosci Biobehav Rev. 2014;47:203–224. doi:10.1016/j.neubiorev.2014.08.008
   PubMed Web of Science ®Google Scholar
• Stice E, Figlewicz DP, Gosnell BA, et al. The contribution of brain reward circuits to the obesity epidemic. Neurosci Biobehav Rev. 2013;37(9):2047–2058. doi:10.1016/j.neubiorev.2012.12.001
   PubMedGoogle Scholar
• Uemura N, Murakami R, Chiba Y, et al. Immunoreactivity of urate transporters, GLUT9 and URAT1, is located in epithelial cells of the choroid plexus of human brains. Neurosci Lett. 2017;659:99–103. doi:10.1016/j.neulet.2017.09.001
   PubMedGoogle Scholar
• Lu W, Xu Y, Shao X, et al. Uric acid produces an inflammatory response through activation of NF-kappaB in the hypothalamus: implications for the pathogenesis of metabolic disorders. Sci Rep. 2015;5(1):12144. doi:10.1038/srep12144
   PubMedGoogle Scholar
• Rocha VZ, Folco EJ, Sukhova G, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res. 2008;103(5):467–476. doi:10.1161/CIRCRESAHA.108.177105
   PubMed Web of Science ®Google Scholar
• Wong N, Fam BC, Cempako GR, et al. Deficiency in interferon-gamma results in reduced body weight and better glucose tolerance in mice. Endocrinology. 2011;152(10):3690–3699. doi:10.1210/en.2011-0288
   PubMedGoogle Scholar
• Abe M, Matsuda M, Kobayashi H, et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol. 2008;28(5):871–877. doi:10.1161/ATVBAHA.107.160663
   PubMedGoogle Scholar
• Wang XA, Zhang R, Jiang D, et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology. 2013;58(2):603–616. doi:10.1002/hep.26368
   PubMedGoogle Scholar
• Eguchi J, Kong X, Tenta M, et al. Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes. 2013;62(10):3394–3403. doi:10.2337/db12-1327
   PubMedGoogle Scholar
• Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808. doi:10.1172/JCI200319246
   PubMed Web of Science ®Google Scholar
• Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 2005;54(8):2305–2313. doi:10.2337/diabetes.54.8.2305
   PubMedGoogle Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35. doi:10.1038/nri978
   PubMed Web of Science ®Google Scholar
• Hume DA. The many alternative faces of macrophage activation. Front Immunol. 2015;6:370. doi:10.3389/fimmu.2015.00370
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–184. doi:10.1172/JCI29881
   PubMed Web of Science ®Google Scholar
• Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12(11):722–734. doi:10.1038/nrm3198
   PubMed Web of Science ®Google Scholar
• Fernandez-Sanchez A, Madrigal-Santillán E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011;12(5):3117–3132. doi:10.3390/ijms12053117
   PubMed Web of Science ®Google Scholar
• Marseglia L, Manti S, D’Angelo G, et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci. 2014;16(1):378–400. doi:10.3390/ijms16010378
   PubMed Web of Science ®Google Scholar
• Fonseca-Alaniz MH, Takada J, Alonso-Vale MIC, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J). 2007;83(5):S192–S203. doi:10.1590/S0021-75572007000700011
   PubMed Web of Science ®Google Scholar
• Lavrovsky Y, Chatterjee B, Clark RA, Roy AK. Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. Exp Gerontol. 2000;35(5):521–532. doi:10.1016/S0531-5565(00)00118-2
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–2180. doi:10.1053/j.gastro.2007.03.059
   PubMed Web of Science ®Google Scholar
• Amirkhizi F, Siassi F, Minaie S, Djalali M, Rahimi A, Chamari M. Is obesity associated with increased plasma lipid peroxidation and oxidative stress in women? ARYA Atheroscler. 2007;2.
   Google Scholar
• Pihl E, Zilmer K, Kullisaar T, et al. Atherogenic inflammatory and oxidative stress markers in relation to overweight values in male former athletes. Int J Obes (Lond). 2006;30(1):141–146. doi:10.1038/sj.ijo.0803068
   PubMedGoogle Scholar
• Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis. 2007;17(8):590–597. doi:10.1016/j.numecd.2006.05.007
   PubMed Web of Science ®Google Scholar
• Tereshin EV. [A role of fatty acids in the development of oxidative stress in aging. A hypothesis]. Adv Gerontol. 2007;20(1):59–65. Russian.
   PubMedGoogle Scholar
• Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584–C596. doi:10.1152/ajpcell.00600.2006
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3–4):e71–e78. doi:10.1159/000345509
   PubMedGoogle Scholar
• Cristobal-Garcia M, García-Arroyo FE, Tapia E, et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev. 2015;2015:535686. doi:10.1155/2015/535686
   PubMed Web of Science ®Google Scholar
• Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258–1269. doi:10.2337/db10-0916
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031. doi:10.1038/nature05414
   PubMed Web of Science ®Google Scholar
• Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–11075. doi:10.1073/pnas.0504978102
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–1023. doi:10.1038/4441022a
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772. doi:10.2337/db06-1491
   PubMed Web of Science ®Google Scholar
• Lewis K, Lutgendorff F, Phan V, et al. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate†. Inflamm Bowel Dis. 2010;16(7):1138–1148. doi:10.1002/ibd.21177
   PubMed Web of Science ®Google Scholar
• Usami M, Kishimoto K, Ohata A, et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res. 2008;28(5):321–328. doi:10.1016/j.nutres.2008.02.012
   PubMed Web of Science ®Google Scholar
• Freeland KR, Wolever TM. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr. 2010;103(3):460–466. doi:10.1017/S0007114509991863
   PubMed Web of Science ®Google Scholar
• Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009;294(1):1–8. doi:10.1111/fml.2009.294.issue-1
   PubMed Web of Science ®Google Scholar
• Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–15723. doi:10.1073/pnas.0407076101
   PubMed Web of Science ®Google Scholar
• Rabot S, Membrez M, Bruneau A, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010;24(12):4948–4959. doi:10.1096/fj.10-164921
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62(1):361–380. doi:10.1146/annurev-med-012510-175505
   PubMedGoogle Scholar
• Aronsson L, Huang Y, Parini P, et al. Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One. 2010;5(9):e13087. doi:10.1371/journal.pone.0013087
   PubMed Web of Science ®Google Scholar
• Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979–984. doi:10.1073/pnas.0605374104
   PubMed Web of Science ®Google Scholar
• Vrieze A, Holleman F, Zoetendal EG, et al. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia. 2010;53(4):606–613. doi:10.1007/s00125-010-1662-7
   PubMed Web of Science ®Google Scholar
• Armougom F, Henry M, Vialettes B, et al. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009;4(9):e7125. doi:10.1371/journal.pone.0007125
   PubMed Web of Science ®Google Scholar
• Santacruz A, Collado MC, García-Valdés L, et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 2010;104(1):83–92. doi:10.1017/S0007114510000176
   PubMed Web of Science ®Google Scholar
• Cani PD, Joly E, Horsmans Y, et al. Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr. 2006;60(5):567–572. doi:10.1038/sj.ejcn.1602350
   PubMed Web of Science ®Google Scholar
• Priebe MG, Wang H, Weening D, et al. Factors related to colonic fermentation of nondigestible carbohydrates of a previous evening meal increase tissue glucose uptake and moderate glucose-associated inflammation. Am J Clin Nutr. 2010;91(1):90–97. doi:10.3945/ajcn.2009.28521
   PubMedGoogle Scholar
• Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009;90(5):1236–1243. doi:10.3945/ajcn.2009.28095
   PubMed Web of Science ®Google Scholar
• Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009;89(6):1751–1759. doi:10.3945/ajcn.2009.27465
   PubMed Web of Science ®Google Scholar
• van Can JG, IJzerman TH, van Loon LJC, et al. Reduced glycaemic and insulinaemic responses following isomaltulose ingestion: implications for postprandial substrate use. Br J Nutr. 2009;102(10):1408–1413. doi:10.1017/S0007114509990687
   PubMedGoogle Scholar
• Guo Z, Zhang J, Wang Z, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016;6(1):20602. doi:10.1038/srep20602
   PubMedGoogle Scholar
• Li G, Yao W, Jiang H. Short-chain fatty acids enhance adipocyte differentiation in the stromal vascular fraction of porcine adipose tissue. J Nutr. 2014;144(12):1887–1895. doi:10.3945/jn.114.198531
   PubMed Web of Science ®Google Scholar
• Vieira AT, Macia L, Galvão I, et al. A Role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol. 2015;67(6):1646–1656. doi:10.1002/art.39107
   PubMed Web of Science ®Google Scholar
• Vieira AT, Galvão I, Macia LM, et al. Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice. J Leukoc Biol. 2017;101(1):275–284. doi:10.1189/jlb.3A1015-453RRR
   PubMed Web of Science ®Google Scholar
• Garcia-Arroyo FE, Gonzaga G, Muñoz-Jiménez I, et al. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018;13(8):e0202901. doi:10.1371/journal.pone.0202901
   PubMed Web of Science ®Google Scholar
• Yu Y, Liu Q, Li H, et al. Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats. Front Microbiol. 2018;9:2233. doi:10.3389/fmicb.2018.02233
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22. doi:10.1172/JCI77812
   PubMed Web of Science ®Google Scholar
• Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7(1):14–24. doi:10.1007/s11684-013-0262-6
   PubMed Web of Science ®Google Scholar
• Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103(2):253–259. doi:10.1172/JCI5001
   PubMedGoogle Scholar
• Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007;104(31):12587–12594. doi:10.1073/pnas.0705408104
   PubMed Web of Science ®Google Scholar
• Perry RJ, Camporez J-P, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745–758. doi:10.1016/j.cell.2015.01.012
   PubMed Web of Science ®Google Scholar
• Perry RJ, Zhang X-M, Zhang D, et al. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Med. 2014;20(7):759–763. doi:10.1038/nm.3579
   PubMedGoogle Scholar
• Previs SF, Cline GW, Shulman GI. A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo. Am J Physiol. 1999;277(1):E154–E160. doi:10.1152/ajpendo.1999.277.1.E154
   PubMedGoogle Scholar
• Samuel VT, Liu Z-X, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345–32353. doi:10.1074/jbc.M313478200
   PubMed Web of Science ®Google Scholar
• Qu X, Seale JP, Donnelly R. Tissue and isoform-selective activation of protein kinase C in insulin-resistant obese Zucker rats - effects of feeding. J Endocrinol. 1999;162(2):207–214. doi:10.1677/joe.0.1620207
   PubMedGoogle Scholar
• Magkos F, Su X, Bradley D, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology. 2012;142(7):1444–6 e2. doi:10.1053/j.gastro.2012.03.003
   PubMed Web of Science ®Google Scholar
• Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle. Adv Physiol Educ. 2014;38(4):308–314. doi:10.1152/advan.00080.2014
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ye J. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharm Sin B. 2012;2(4):341–349. doi:10.1016/j.apsb.2012.06.010
   PubMedGoogle Scholar
• Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603–608. doi:10.2337/diabetes.54.3.603
   PubMed Web of Science ®Google Scholar
• Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506–2514. doi:10.1007/s00125-011-2204-7
   PubMed Web of Science ®Google Scholar
• Zhou L, Podolsky N, Sang Z, et al. The medial amygdalar nucleus: a novel glucose-sensing region that modulates the counterregulatory response to hypoglycemia. Diabetes. 2010;59(10):2646–2652. doi:10.2337/db09-0995
   PubMedGoogle Scholar
• Choi HK, Mount DB, Reginato AM, et al. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516. doi:10.7326/0003-4819-143-7-200510040-00009
   PubMed Web of Science ®Google Scholar
• Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(8):928–933. doi:10.1253/circj.69.928
   PubMed Web of Science ®Google Scholar
• Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol. 1997;10(4):188–191.
   PubMedGoogle Scholar
• Scott FW, Trick KD, Stavric B, et al. Uric acid-induced decrease in rat insulin secretion. Proc Soc Exp Biol Med. 1981;166(1):123–128. doi:10.3181/00379727-166-41033
   PubMedGoogle Scholar
• Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925–932. doi:10.1016/j.jhep.2015.11.022
   PubMed Web of Science ®Google Scholar
• Cicerchi C, Li N, Kratzer J, et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J. 2014;28(8):3339–3350. doi:10.1096/fsb2.v28.8
   PubMed Web of Science ®Google Scholar
• Epingeac M, Gaman MA, Diaconu CC, Gad M, Gaman AM. The evaluation of oxidative stress levels in obesity. Revista Chimie Bucharest Original Ed. 2019;70:2241–2244.
   Web of Science ®Google Scholar
• Matsuoka TA, Kaneto H, Miyatsuka T, et al. Regulation of MafA expression in pancreatic beta-cells in db/db mice with diabetes. Diabetes. 2010;59(7):1709–1720. doi:10.2337/db08-0693
   PubMedGoogle Scholar
• Kawamori D, Kajimoto Y, Kaneto H, et al. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH(2)-terminal kinase. Diabetes. 2003;52(12):2896–2904. doi:10.2337/diabetes.52.12.2896
   PubMed Web of Science ®Google Scholar
• Miric DJ, Kisic BM, Filipovic-Danic S, et al. Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy. J Diabetes Res. 2016;2016:4370490. doi:10.1155/2016/4370490
   PubMed Web of Science ®Google Scholar
• Washio KW, Kusunoki Y, Murase T, et al. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans. Metabolism. 2017;70:51–56. doi:10.1016/j.metabol.2017.01.031
   PubMed Web of Science ®Google Scholar
• Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924–929. doi:10.1097/JIM.0000000000000242
   PubMed Web of Science ®Google Scholar
• Isık H, Aynıoglu O, Tımur H, et al. Is Xanthine oxidase activity in polycystic ovary syndrome associated with inflammatory and cardiovascular risk factors? J Reprod Immunol. 2016;116:98–103. doi:10.1016/j.jri.2016.06.002
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Yamauchi Y, Murase T, et al. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients. PLoS One. 2017;12(8):e0182699. doi:10.1371/journal.pone.0182699
   PubMedGoogle Scholar
• Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625–F631. doi:10.1152/ajprenal.00140.2005
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Lanaspa MA, Ishimoto T, et al. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015;58(9):1993–2002. doi:10.1007/s00125-015-3650-4
   PubMed Web of Science ®Google Scholar
• Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223. doi:10.1186/ar3199
   PubMed Web of Science ®Google Scholar
• Choi YJ, Shin H-S, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94(10):1114–1125. doi:10.1038/labinvest.2014.98
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim Y-G, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–1106. doi:10.1161/hy1101.092839
   PubMed Web of Science ®Google Scholar
• Perez-Pozo SE, Schold J, Nakagawa T, et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond). 2010;34(3):454–461. doi:10.1038/ijo.2009.259
   PubMed Web of Science ®Google Scholar
• DeBosch BJ, Kluth O, Fujiwara H, et al. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5(1):4642. doi:10.1038/ncomms5642
   PubMedGoogle Scholar
• El Din UAS, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8(5):537–548. doi:10.1016/j.jare.2016.11.004
   PubMed Web of Science ®Google Scholar
• Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol. 1998;274(4):E692–E699. doi:10.1152/ajpendo.1998.274.4.E692
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Snell-Bergeon JK, McFann K, et al. Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. J Diabetes Complications. 2014;28(3):298–304. doi:10.1016/j.jdiacomp.2013.12.007
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Epperson LE, Li N, et al. Opposing activity changes in AMP deaminase and AMP-activated protein kinase in the hibernating ground squirrel. PLoS One. 2015;10(4):e0123509. doi:10.1371/journal.pone.0123509
   PubMedGoogle Scholar
• Xu W, Huang Y, Li L, et al. Hyperuricemia induces hypertension through activation of renal epithelial sodium channel (ENaC). Metabolism. 2016;65(3):73–83. doi:10.1016/j.metabol.2015.10.026
   PubMed Web of Science ®Google Scholar
• Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study. Clin Drug Investig. 2015;35(12):823–831. doi:10.1007/s40261-015-0349-8
   PubMed Web of Science ®Google Scholar
• Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013;347(oct01 3):f5648. doi:10.1136/bmj.f5648
   PubMedGoogle Scholar
• Cirillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol. 2006;17(12 Suppl 3):S165–S168. doi:10.1681/ASN.2006080909
   PubMed Web of Science ®Google Scholar
• Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010;25(6):1865–1869. doi:10.1093/ndt/gfp740
   PubMed Web of Science ®Google Scholar
• Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56(4):369–381. doi:10.1016/j.pcad.2013.10.016
   PubMed Web of Science ®Google Scholar
• Kaltman AJ, Goldring RM. Role of circulatory congestion in the cardiorespiratory failure of obesity. Am J Med. 1976;60(5):645–653. doi:10.1016/0002-9343(76)90499-X
   PubMed Web of Science ®Google Scholar
• Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med. 1987;147(10):1725–1728. doi:10.1001/archinte.1987.00370100039008
   PubMedGoogle Scholar
• Messerli FH. Cardiopathy of obesity–a not-so-Victorian disease. N Engl J Med. 1986;314(6):378–380. doi:10.1056/NEJM198602063140608
   PubMedGoogle Scholar
• Ku CS, Lin S-L, Wang D-J, et al. Left ventricular filling in young normotensive obese adults. Am J Cardiol. 1994;73(8):613–615. doi:10.1016/0002-9149(94)90347-6
   PubMedGoogle Scholar
• Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26(5):968–976. doi:10.1161/01.ATV.0000216787.85457.f3
   PubMed Web of Science ®Google Scholar
• Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237–242. doi:10.1016/0895-4356(88)90127-8
   PubMed Web of Science ®Google Scholar
• Storhaug HM, Norvik JV, Toft I, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromso Study. BMC Cardiovasc Disord. 2013;13(1):115. doi:10.1186/1471-2261-13-115
   PubMedGoogle Scholar
• Chen JH, Lan J-L, Cheng C-F, et al. Effect of Urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS One. 2015;10(12):e0145193. doi:10.1371/journal.pone.0145193
   PubMedGoogle Scholar
• Chen JH, Lan J-L, Cheng C-F, et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42(9):1694–1701. doi:10.3899/jrheum.141542
   PubMed Web of Science ®Google Scholar
• Battelli MG, Bortolotti M, Polito L, et al. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2018;1864(8):2557–2565. doi:10.1016/j.bbadis.2018.05.003
   PubMed Web of Science ®Google Scholar
• Ando K, Takahashi H, Watanabe T, et al. Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease. J Atheroscler Thromb. 2016;23(8):932–939. doi:10.5551/jat.33951
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3–4):e71–8. doi:10.1159/000345509
   PubMedGoogle Scholar
• Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. 2011;13(1):71–76. doi:10.1007/s11912-010-0139-7
   PubMed Web of Science ®Google Scholar
• Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011;32(4):550–570. doi:10.1210/er.2010-0030
   PubMed Web of Science ®Google Scholar
• Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–1503. doi:10.1038/nm.2492
   PubMed Web of Science ®Google Scholar
• Tessitore L, Vizio B, Pesola D, et al. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol. 2004;24(6):1529–1535.
   PubMedGoogle Scholar
• Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest. 2012;122(11):4243–4256. doi:10.1172/JCI63930
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–949. doi:10.1161/01.RES.0000163635.62927.34
   PubMed Web of Science ®Google Scholar
• Doyle SL, Donohoe CL, Lysaght J, et al. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc. 2012;71(1):181–189. doi:10.1017/S002966511100320X
   PubMed Web of Science ®Google Scholar
• Park J, Morley TS, Kim M, et al. Obesity and cancer–mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–465. doi:10.1038/nrendo.2014.94
   PubMed Web of Science ®Google Scholar
• Endo H, Hosono K, Uchiyama T, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut. 2011;60(10):1363–1371. doi:10.1136/gut.2010.235754
   PubMed Web of Science ®Google Scholar
• Saxena NK, Fu PP, Nagalingam A, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010;139(5):1762–1765. doi:10.1053/j.gastro.2010.07.001
   PubMedGoogle Scholar
• Kim AY, Lee YS, Kim KH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441–1452. doi:10.1210/me.2009-0498
   PubMed Web of Science ®Google Scholar
• Denzel MS, Hebbard LW, Shostak G, et al. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res. 2009;15(10):3256–3264. doi:10.1158/1078-0432.CCR-08-2661
   PubMedGoogle Scholar
• Mendonca FM, de Sousa FR, Barbosa AL, et al. Metabolic syndrome and risk of cancer: which link? Metabolism. 2015;64(2):182–189. doi:10.1016/j.metabol.2014.10.008
   PubMed Web of Science ®Google Scholar
• Găman M, Epingeac ME, Găman A. The evaluation of oxidative stress and high-density lipoprotein cholesterol levels in diffuse large B-cell lymphoma. Revista Chimie. 2019;70(3):977–980. doi:10.37358/RC.19.3.7043
   Google Scholar
• Brown JM, McIntosh MK. Conjugated linoleic acid in humans: regulation of adiposity and insulin sensitivity. J Nutr. 2003;133(10):3041–3046. doi:10.1093/jn/133.10.3041
   PubMed Web of Science ®Google Scholar
• Naugler WE, Karin M. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109–119. doi:10.1016/j.molmed.2007.12.007
   PubMed Web of Science ®Google Scholar
• Park J, Sarode VR, Euhus D, et al. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proc Natl Acad Sci U S A. 2012;109(51):21058–21063. doi:10.1073/pnas.1214400109
   PubMed Web of Science ®Google Scholar
• Wang ZV, Mu J, Schraw TD, et al. PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. Diabetes. 2008;57(8):2137–2148. doi:10.2337/db07-1631
   PubMedGoogle Scholar
• Xie Y, Xu P, Liu K, et al. Hyperuricemia and gout are associated with cancer incidence and mortality: a meta-analysis based on cohort studies. J Cell Physiol. 2019;234(8):14364–14376. doi:10.1002/jcp.v234.8
   PubMed Web of Science ®Google Scholar
• Fini MA, Elias A, Johnson RJ, et al. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1(1):16. doi:10.1186/2001-1326-1-16
   PubMedGoogle Scholar
• Battelli MG, Bortolotti M, Polito L, et al. Metabolic syndrome and cancer risk: the role of xanthine oxidoreductase. Redox Biol. 2019;21:101070. doi:10.1016/j.redox.2018.101070
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72(1):219–246. doi:10.1146/annurev-physiol-021909-135846
   PubMed Web of Science ®Google Scholar
• Liao X, Sharma N, Kapadia F, et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest. 2011;121(7):2736–2749. doi:10.1172/JCI45444
   PubMed Web of Science ®Google Scholar
• Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11(11):738–749. doi:10.1038/nri3071
   PubMed Web of Science ®Google Scholar
• Toubal A, Clément K, Fan R, et al. SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation. J Clin Invest. 2013;123(1):362–379. doi:10.1172/JCI64052
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797–802. doi:10.1136/annrheumdis-2013-203970
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Wadden TA, Longo DL. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–266. doi:10.1056/NEJMra1514009
   PubMed Web of Science ®Google Scholar
• Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018;1411(1):106–119. doi:10.1111/nyas.13542
   PubMedGoogle Scholar
• Solas M, Milagro FI, Martínez-Urbistondo D, et al. Precision obesity treatments including pharmacogenetic and nutrigenetic approaches. Trends Pharmacol Sci. 2016;37(7):575–593. doi:10.1016/j.tips.2016.04.008
   PubMedGoogle Scholar
• Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013;62(2):490–497. doi:10.2337/db12-0598
   PubMed Web of Science ®Google Scholar
• Fani L, Bak S, Delhanty P, et al. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes (Lond). 2014;38(2):163–169. doi:10.1038/ijo.2013.80
   PubMedGoogle Scholar
• Low MJ. Neuroendocrinology: new hormone treatment for obesity caused by POMC-deficiency. Nat Rev Endocrinol. 2016;12(11):627–628. doi:10.1038/nrendo.2016.156
   PubMedGoogle Scholar
• Kuhnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240–246. doi:10.1056/NEJMoa1512693
   PubMed Web of Science ®Google Scholar
• Clement K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551–555. doi:10.1038/s41591-018-0015-9
   PubMed Web of Science ®Google Scholar
• Christensen M, Vedtofte L, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103–3109. doi:10.2337/db11-0979
   PubMed Web of Science ®Google Scholar
• Norregaard PK, Deryabina MA, Tofteng Shelton P, et al. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes Metab. 2018;20(1):60–68. doi:10.1111/dom.2018.20.issue-1
   PubMed Web of Science ®Google Scholar
• Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757. doi:10.1038/nchembio.209
   PubMed Web of Science ®Google Scholar
• Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258–2266. doi:10.2337/db09-0278
   PubMed Web of Science ®Google Scholar
• Cegla J, Troke RC, Jones B, et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014;63(11):3711–3720. doi:10.2337/db14-0242
   PubMed Web of Science ®Google Scholar
• Tan TM, Field BCT, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131–1138. doi:10.2337/db12-0797
   PubMed Web of Science ®Google Scholar
• Tschop MH, Finan B, Clemmensen C, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51–62. doi:10.1016/j.cmet.2016.06.021
   PubMed Web of Science ®Google Scholar
• Finan B, Müller TD, Clemmensen C, et al. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med. 2016;22(5):359–376. doi:10.1016/j.molmed.2016.03.005
   PubMed Web of Science ®Google Scholar
• Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36. doi:10.1038/nm.3761
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–128. doi:10.1016/j.drudis.2014.10.003
   PubMed Web of Science ®Google Scholar
• Giralt M, Gavalda-Navarro A, Villarroya F. Fibroblast growth factor-21, energy balance and obesity. Mol Cell Endocrinol. 2015;418(Pt 1):66–73. doi:10.1016/j.mce.2015.09.018
   PubMedGoogle Scholar
• Fisher FM, Maratos-Flier E. Understanding the Physiology of FGF21. Annu Rev Physiol. 2016;78(1):223–241. doi:10.1146/annurev-physiol-021115-105339
   PubMed Web of Science ®Google Scholar
• Badman MK, Koester A, Flier JS, et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150(11):4931–4940. doi:10.1210/en.2009-0532
   PubMedGoogle Scholar
• Cuevas-Ramos D, Aguilar-Salinas CA. Modulation of energy balance by fibroblast growth factor 21. Horm Mol Biol Clin Investig. 2016;30(1).
   PubMedGoogle Scholar
• Habegger KM, Stemmer K, Cheng C, et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013;62(5):1453–1463. doi:10.2337/db12-1116
   PubMed Web of Science ®Google Scholar
• Ye X, Qi J, Ren G, et al. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice. Endocrine. 2015;49(3):683–692. doi:10.1007/s12020-014-0503-8
   PubMedGoogle Scholar
• Weng Y, Chabot JR, Bernardo B, et al. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS One. 2015;10(3):e0119104. doi:10.1371/journal.pone.0119104
   PubMed Web of Science ®Google Scholar
• Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76(11):1870–1882. doi:10.1136/annrheumdis-2017-211472
   PubMed Web of Science ®Google Scholar
• Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017;36(12):2637–2644. doi:10.1007/s10067-017-3851-y
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–325. doi:10.1002/art.20405
   PubMed Web of Science ®Google Scholar
• Robinson PC. Gout - An update of aetiology, genetics, co-morbidities and management. Maturitas. 2018;118:67–73. doi:10.1016/j.maturitas.2018.10.012
   PubMed Web of Science ®Google Scholar
• Pascart T, Richette P. Current and future therapies for gout. Expert Opin Pharmacother. 2017;18(12):1201–1211. doi:10.1080/14656566.2017.1351945
   PubMed Web of Science ®Google Scholar
• Soskind R, Abazia DT, Bridgeman MB. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother. 2017;18(11):1115–1125. doi:10.1080/14656566.2017.1349099
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–772. doi:10.1161/CIRCULATIONAHA.116.021887
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230. doi:10.1007/s40265-019-1057-0
   PubMed Web of Science ®Google Scholar
• Borghi C, Palazzuoli A, Landolfo M, Cosentino E. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. Heart Fail Rev. 2019;25(1):43–51.
   Google Scholar
• Bussler S, Penke M, Flemming G, et al. Novel insights in the metabolic syndrome in childhood and adolescence. Horm Res Paediatr. 2017;88(3–4):181–193. doi:10.1159/000479510
   PubMedGoogle Scholar